Skip to main content

A Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis in Patients with Suspected Type 3 Sphincter of Oddi Dysfunction

Digestive Diseases and Sciences volume 60, pages 2509–2515 (2015)Cite this article

An Erratum to this article was published on 05 October 2015

Abstract

Background and Aim

Recent data have suggested that rectal indomethacin can also reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). The aim of this study was to determine whether prophylactic rectal indomethacin with PD stenting would reduce the incidence and severity of PEP compared to PD stenting alone in patients undergoing manometry for suspected SOD type 3.

Patients and Methods

A retrospective review of consecutive patients who underwent an ERCP with manometry for suspected SOD type 3 was performed. Patients were divided into two groups: (a) those who received a prophylactic PD stent (n = 285) and (b) those who received a prophylactic PD stent and a single dose of 100-mg indomethacin suppositories after ERCP (n = 57). The rate of PEP was compared between the two groups.

Results

The two patient groups were similar with regard to patient and procedure risk factors for PEP. Post-ERCP pancreatitis developed in 22 % patients. There was no significant difference in the incidence of PEP in the PD stent group compared to the PD stent and indomethacin group (23 vs. 18 %, respectively; p = 0.39). Moderate-to-severe pancreatitis developed in 21 (7 %) patients in the PD stent group compared to 5 (9 %) patients in the PD stent and indomethacin group (p = 0.78). Among patients with PEP, the median length of hospital stay was not significantly longer in the PD stent group compared to the PD stent and indomethacin group (6 vs. 4 days, respectively; p = 0.11).

Conclusions

In patients with suspected SOD type 3, prophylactic rectally administered indomethacin with PD stenting was not observed to affect the incidence or severity of post-ERCP pancreatitis when compared to PD stenting alone.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Maranki J, Yeaton P. Prevention of post-ERCP pancreatitis. Curr Gastroenterol Rep. 2013;15:352.

    Article  PubMed  Google Scholar 

  2. Behar J, Corazziari E, Guelrud M, Hogan W, Sherman S, Toouli J. Functional gallbladder and sphincter of oddi disorders. Gastroenterology. 2006;130:1498–1509.

    Article  PubMed  Google Scholar 

  3. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37:383–393.

    CAS  Article  PubMed  Google Scholar 

  4. Gottlieb K, Sherman S. ERCP and biliary endoscopic sphincterotomy-induced pancreatitis. Gastrointest Endosc Clin N Am. 1998;8:87–114.

    CAS  PubMed  Google Scholar 

  5. Elton E, Howell DA, Parsons WG, Qaseem T, Hanson BL. Endoscopic pancreatic sphincterotomy: indications, outcome, and a safe stentless technique. Gastrointest Endosc. 1998;47:240–249.

    CAS  Article  PubMed  Google Scholar 

  6. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425–434.

    CAS  Article  PubMed  Google Scholar 

  7. Masci E, Mariani A, Curioni S, Testoni PA. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy. 2003;35:830–834.

    CAS  Article  PubMed  Google Scholar 

  8. Tarnasky PR, Palesch YY, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology. 1998;115:1518–1524.

    CAS  Article  PubMed  Google Scholar 

  9. Fazel A, Quadri A, Catalano MF, Meyerson SM, Geenen JE. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc. 2003;57:291–294.

    Article  PubMed  Google Scholar 

  10. Beltz S, Sarkar A, Loren DE, Andrel J, Kowalski T, Siddiqui AA. Risk stratification for the development of post-ERCP pancreatitis by sphincter of Oddi dysfunction classification. South Med J. 2013;106:298–302.

    Article  PubMed  Google Scholar 

  11. Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008;57:1262–1267.

    CAS  Article  PubMed  Google Scholar 

  12. Ding X, Chen M, Huang S, Zhang S, Zou X. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc. 2012;76:1152–1159.

    Article  PubMed  Google Scholar 

  13. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–111.

    Article  PubMed  Google Scholar 

  14. Freeman ML, Overby C, Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc. 2004;59:8–14.

    Article  PubMed  Google Scholar 

  15. Saad AM, Fogel EL, McHenry L, et al. Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results. Gastrointest Endosc. 2008;67:255–261.

    Article  PubMed  Google Scholar 

  16. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366:1414–1422.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  17. Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol. 2006;101:139–147.

    Article  PubMed  Google Scholar 

  18. Rabenstein T, Hahn EG. Post-ERCP pancreatitis: new momentum. Endoscopy. 2002;34:325–329.

    CAS  Article  PubMed  Google Scholar 

  19. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004;59:845–864.

    Article  PubMed  Google Scholar 

  20. Sherman S. What is the role of ERCP in the setting of abdominal pain of pancreatic or biliary origin (suspected sphincter of Oddi dysfunction)? Gastrointest Endosc. 2002;56:S258–S266.

    Article  PubMed  Google Scholar 

  21. Maldonado ME, Brady PG, Mamel JJ, Robinson B. Incidence of pancreatitis in patients undergoing sphincter of Oddi manometry (SOM). Am J Gastroenterol. 1999;94:387–390.

    CAS  Article  PubMed  Google Scholar 

  22. Fogel EL, Eversman D, Jamidar P, Sherman S, Lehman GA. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy. 2002;34:280–285.

    CAS  Article  PubMed  Google Scholar 

  23. Otsuka T, Kawazoe S, Nakashita S, et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol. 2012;47:912–917.

    CAS  Article  PubMed  Google Scholar 

  24. Geenen JE, Hogan WJ, Dodds WJ, Toouli J, Venu RP. The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med. 1989;320:82–87.

    CAS  Article  PubMed  Google Scholar 

  25. Neoptolemos JP, Bailey IS, Carr-Locke DL. Sphincter of Oddi dysfunction: results of treatment by endoscopic sphincterotomy. Br J Surg. 1988;75:454–459.

    CAS  Article  PubMed  Google Scholar 

  26. Cotton PB, Durkalski V, Romagnuolo J, et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. JAMA. 2014;311:2101–2109.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded entirely through existing intramural funds and salary support.

Conflict of interest

None.

Author information

Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Ali A. Siddiqui, Devi Patel, Jeremy Kaplan, Andrew H. Zabolotsky, David Loren, Thomas Kowalski, Saad S. Ghumman & Umar Hayat

  2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA

    Douglas G. Adler

  3. Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA

    Satish Munigal

  4. Division of Gastroenterology, Northeast Alabama Regional Medical Center, Anniston, AL, USA

    Mohamad A. Eloubeidi

Authors
  1. Ali A. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Devi Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeremy Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew H. Zabolotsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Loren
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Kowalski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Saad S. Ghumman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Douglas G. Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Satish Munigal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Umar Hayat
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mohamad A. Eloubeidi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali A. Siddiqui.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Siddiqui, A.A., Patel, D., Kaplan, J. et al. A Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis in Patients with Suspected Type 3 Sphincter of Oddi Dysfunction. Dig Dis Sci 60, 2509–2515 (2015). https://doi.org/10.1007/s10620-015-3643-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3643-7

Keywords

  • Acute pancreatitis
  • Endoscopic retrograde cholangiopancreatography
  • Indomethacin
  • Sphincter of Oddi dysfunction